Status:
COMPLETED
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans
Lead Sponsor:
Leiden University Medical Center
Collaborating Sponsors:
Dutch Diabetes Research Foundation
Conditions:
Insulin Resistance
Dyslipidemia
Eligibility:
MALE
20-40 years
Phase:
NA
Brief Summary
We hypothesized that short-term treatment with AP drugs induces insulin resistance through a mechanistic route that is independent of weight gain and that atypical drugs exert stronger effects than ty...
Eligibility Criteria
Inclusion
- Healthy men, with and without a positive family history of schizophrenia.
- 20 kg/m2 \< BMI \< 26 kg/m2
- Age 20-40 years
- Fasting plasma glucose \< 6 mmo/L
Exclusion
- FPG \> 6 mmol/L
- BMI \> 26 kg/m2
- Psychiatric disorders and/or use of antipsychotic or antidepressants drugs at present or in the past.
- Any significant chronic disease
- Renal, hepatic or endocrine disease
- Use of medication known to influence lipolysis and/or glucose metabolism
- Total cholesterol \> 7mmol/L and/or triglycerides \> 2 mmol/L
- Recent weight changes or attempts to loose weight (\> 3 kg weight gain or loss, within the last 3 months)
- Difficulties to insert an intravenous catheter
- Smoking (current)
- Severe claustrophobia (ventilated hood)
- Recent blood donation (within the last 2 months)
- Recent participation in other research projects (within the last 3 months), participation in 2 or more projects in one year
- Extensive sporting activities (more than 10 hours of exercise per week)
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2004
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00625170
Start Date
May 1 2004
End Date
December 1 2004
Last Update
February 28 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Leiden University Medical Center
Leiden, Netherlands, 2300 RC